£13.25
2.43% yesterday
London, Oct 10, 05:35 pm CET
ISIN
GB0009223206
Symbol
SN

Smith & Nephew Stock price

£13.25
-0.77 5.48% 1M
+3.75 39.47% 6M
+3.57 36.89% YTD
+2.58 24.17% 1Y
+3.88 41.47% 3Y
-0.23 1.68% 5Y
+4.27 47.62% 10Y
+10.03 311.72% 20Y
London, Closing price Fri, Oct 10 2025
-0.33 2.43%

Key metrics

Basic
Market capitalization
£11.5b
Enterprise Value
£13.6b
Net debt
£2.1b
Cash
£506.3m
Shares outstanding
876.0m
Valuation (TTM | estimate)
P/E
31.5 | 15.4
P/S
2.6 | 2.5
EV/Sales
3.1 | 2.9
EV/FCF
22.8
P/B
2.8
Dividends
DPS
£0.29
Yield 1Y | 5Y
2.2% | 2.5%
Growth 1Y | 5Y
-5.9% | -0.9%
Payout 1Y | 3Y
81.7% | 117.2%
Increased
0 Years
Financials (TTM | estimate)
Revenue
£4.5b | £4.7b
EBITDA
£797.6m | £1.2b
EBIT
£667.3m | £851.5m
Net Income
£367.7m | £754.1m
Free Cash Flow
£596.9m
Growth (TTM | estimate)
Revenue
5.4% | 7.8%
EBITDA
19.9% | 48.6%
EBIT
28.0% | 27.8%
Net Income
61.0% | 144.4%
Free Cash Flow
164.8%
Margin (TTM | estimate)
Gross
70.0%
EBITDA
17.9% | 26.6%
EBIT
15.0%
Net
8.3% | 16.1%
Free Cash Flow
13.4%
Financial Health
Equity Ratio
50.9%
Return on Equity
7.8%
ROCE
9.7%
ROIC
8.4%
Debt/Equity
0.6
More
EPS
£0.4
FCF per Share
£0.7
Short interest
143.0%
Employees
17k
Rev per Employee
£250.0k
Show more

Is Smith & Nephew a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,999 stocks worldwide.

Smith & Nephew Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Smith & Nephew forecast:

13x Buy
57%
10x Hold
43%

Analyst Opinions

23 Analysts have issued a Smith & Nephew forecast:

Buy
57%
Hold
43%

Financial data from Smith & Nephew

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4,452 4,452
5% 5%
100%
- Direct Costs 1,334 1,334
2% 2%
30%
3,118 3,118
7% 7%
70%
- Selling and Administrative Expenses 2,099 2,099
4% 4%
47%
- Research and Development Expense 221 221
5% 5%
5%
798 798
20% 20%
18%
- Depreciation and Amortization 130 130
9% 9%
3%
EBIT (Operating Income) EBIT 667 667
28% 28%
15%
Net Profit 368 368
61% 61%
8%

In millions GBP.

Don't miss a Thing! We will send you all news about Smith & Nephew directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Deepak Nath
Employees 17,349
Founded 1856
Website www.smith-nephew.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today